Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B Acute Lymphoblastic Leukemia (B ALL)
NCT Number:
NCT02981628
Phase:
II
Protocol Type:
Treatment
Age Group:
Both
Disease Sites:
Lymphoid Leukemia
Study Objectives:
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Study Documents
(MUSC NetID required for document access)